Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics.

Для цитирования: Gundugurti Prasad Rao, Komaravalli Prasanna Latha, Chatterjee Amrita, Byregowda Bharath Harohalli, Kocherlakota Chandrashekhar, Kothapalli Kumar Sd. Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics.. Asian journal of psychiatry. 2026. DOI: 10.1016/j.ajp.2026.105182.